Treatment Table 1. CHADS2
C H A D S
CHADS2
Patients With Nonrheumatic Atrial Fibrillation Risk Factor
Recent Congestive heart failure exacerbation History of Hypertension Age ≥ 75 years
Diabetes mellitus Prior history of Stroke or transient ischemic attack Score for Assessment of Stroke Risk in
Points 1 1 1 1 2
stroke or transient ischemic attack. Other risk factors for stroke include age 65-74 years and female gender, which have been more consistently validated, and vascular disease, which has been less well validated.
= congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior Table 4. Drugs
Class/Agent (Brand)
Oral Anticoagulants Antiplatelet Aspirin
Clopidogrel (Plavix®
)
Aspirin/extended- release dipyridamole (Aggrenox®
)
Cilostazol (Pletal®
) Triflusal VKA
Warfarin (Coumadin® Jantoven®
)
Dabigatran (Pradaxa®
, PO
Direct thrombin inhibitor )
Factor Xa Inhibitor )
Rivaroxaban (Xarelto®
PO Adjust to INR ClCr
150 mg bid ClCr
75 mg bid
PO with the evening meal
ClCr
> 30 mL/min: 15-30 mL/min:
20 mg once daily ClCr
15 mg once daily
> 50 mL/min: 15-50 mL/min:
FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF
FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF (approved aſter submission of the guidelines)
PO PO
100 mg bid on empty stomach
Indicated for the reduction of symptoms of intermittent claudication
300-900 mg daily Not available in the USA Route Dose
PO PO
PO
75-325 mg once daily 75 mg once daily 25 mg/200 mg bid
Comments
